Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2030

Study Completion Date

June 1, 2031

Conditions

SLC13A5 Citrate Transporter Disorder

Interventions

DRUG

TSHA-105

AAV9/SLC13A5

Trial Locations (1)

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors

lead

TESS Research Foundation

OTHER

NCT07102524 - Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder | Biotech Hunter | Biotech Hunter